Key details about broadly neutralizing antibodies provide insights for universal flu vaccine
New research on polyreactive broadly neutralizing antibodies shows the challenges of balancing an effective immune response.
CAR T-cell therapy found equivalent to standard of care as second-line treatment for aggressive non-Hodgkin lymphoma
New research shows CAR T-cell therapy tisagenlecleucel (tisa-cel) didn't improve event-free survival when compared to the standard of care as a second-line treatment for patients with aggressive non-Hodgkin lymphoma.
Kovler Clinical Trials Testing New Treatments, Advancing Science
The center’s clinical trials are exploring promising new treatments for diabetes, with patients’ help
